Physicians' Academy for Cardiovascular Education

Icosapent Ethyl Resources

Recent clinical insights with icosapent ethyl

10' education - Oct. 3, 2022 - Prof. Deepak Bhatt, MD

Finding a place for fish oil in CVD prevention

10' education - Sep. 7, 2022 - Prof. Chris Packard, PhD

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

A call to solve the controversy on omega-3FAs trials

5' education - May 17, 2021 - Prof. Eileen Handberg, PhD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides

10' education - Sep. 23, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Fish oil treatment reduces several plaque parameters after 9 months

3' education - Nov. 18, 2019 - Prof. Matthew Budoff - AHA 2019, Philadelphia

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Recent clinical insights with icosapent ethyl

10' education - Oct. 3, 2022 - Prof. Deepak Bhatt, MD
It has been 3 years since the presentation and publication of the REDUCE-IT trial. What are more recent insights from subsequent analyses of the REDUCE-IT trial?

It has been 3 years since the presentation and publication of the REDUCE-IT trial. What are more recent insights from subsequent analyses of the REDUCE-IT trial?

Icosapent ethyl reduces MI overall and MI subtypes

News - Sep. 7, 2022

ESC 2022 An analysis of the REDUCE-IT trial showed that use of icosapent ethyl reduces the rate of MI overall, and of MI subtypes including STEMI, NSTEMI, MI leading to cardiac arrest and resuscitated MI, when compared to placebo.

Finding a place for fish oil in CVD prevention

10' education - Sep. 7, 2022 - Prof. Chris Packard, PhD
After presenting findings from the REDUCE-IT trial, prof. Packard discusses the place for icosapent ethyl. He talks about the need for a tailored approach in ASCVD patients with high risk.

After presenting findings from the REDUCE-IT trial, prof. Packard discusses the place for icosapent ethyl. He talks about the need for a tailored approach in ASCVD patients with high risk.

Final guidance by NICE in UK on recommendation for use of icosapent ethyl

News - July 19, 2022

NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.

CAC score can identify REDUCE-IT-eligible patients who benefit most from icosapent ethyl

Literature - July 18, 2022 - Mortensen MB, et al. - Eur J Prev Cardiol. 2022

The REDUCE-IT trial showed that treatment with icosapent ethyl is effective in patients receiving a statin who meet certain biochemical criteria. The CAC score may help to identify patients who would benefit most from this treatment.

NICE publishes final draft guidance on icosapent ethyl

News - June 13, 2022

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.

E-learning CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!

Icosapent ethyl decreases CVD risk after MI

Literature - May 16, 2022 - Gaba P et al. - J Am Coll Cardiol. 2022

In a subgroup analysis of REDUCE-IT, additional treatment with icosapent ethyl resulted in less ischemic events in statin-treated patients with prior MI.

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Consistent benefit of icosapent ethyl across background statin agent and category

Literature - Jan. 12, 2022 - Singh N et al. - J Am Coll Cardiol. 2022

There was no difference of icosapent ethyl efficacy among statin agents and statin categories (lipophilic vs. lipophobic statins) in an exploratory analysis of the REDUCE-IT trial.